StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.78+0.08 (+2.16%)

Close on Nov 18, 2026Market cap $474.43MP/E –Yield –

Aquestive Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Aquestive Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$45.37M. For fiscal 2025 it was -$52.43M. The highest annual figure on record is $5.82M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$52.43M–
FY2024Dec 31, 2024-$35.76M–
FY2023Dec 31, 2023-$6.38M–
FY2022Dec 31, 2022-$9.82M–
FY2021Dec 31, 2021-$32.98M–
FY2020Dec 31, 2020-$45.46M–
FY2019Dec 31, 2019-$60.21M–
FY2018Dec 31, 2018-$12.99M-323.1%
FY2017Dec 31, 2017$5.82M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.44M–
Q1 FY2026Mar 31, 2026-$14.81M–
Q4 FY2025Dec 31, 2025-$8.47M–
Q3 FY2025Sep 30, 2025-$12.65M–
Q2 FY2025Jun 30, 2025-$7.91M–
Q1 FY2025Mar 31, 2025-$23.40M–
Q4 FY2024Dec 31, 2024-$6.49M–
Q3 FY2024Sep 30, 2024-$11.88M–
Q2 FY2024Jun 30, 2024-$7.01M–
Q1 FY2024Mar 31, 2024-$10.38M-217.8%
Q4 FY2023Dec 31, 2023-$4.94M-158.7%
Q3 FY2023Sep 30, 2023-$2.35M-183.6%
Q2 FY2023Jun 30, 2023-$7.91M–
Q1 FY2023Mar 31, 2023$8.82M–
Q4 FY2022Dec 31, 2022$8.42M–
Q3 FY2022Sep 30, 2022$2.81M–
Q2 FY2022Jun 30, 2022-$6.56M–
Q1 FY2022Mar 31, 2022-$14.48M–
Q4 FY2021Dec 31, 2021-$8.06M–
Q3 FY2021Sep 30, 2021-$9.07M–
Q2 FY2021Jun 30, 2021-$1.76M–
Q1 FY2021Mar 31, 2021-$14.10M–
Q4 FY2020Dec 31, 2020-$13.51M–
Q3 FY2020Sep 30, 2020-$8.31M–
Q2 FY2020Jun 30, 2020-$10.00M–
Q1 FY2020Mar 31, 2020-$13.64M–
Q4 FY2019Dec 31, 2019-$10.58M–
Q3 FY2019Sep 30, 2019-$14.79M-1983.9%
Q2 FY2019Jun 30, 2019-$17.17M–
Q1 FY2019Mar 31, 2019-$17.68M-213.1%
Q4 FY2018Dec 31, 2018-$2.81M–
Q1 FY2018Mar 31, 2018$785.00K–
Q4 FY2017Dec 31, 2017-$7.41M–
Q3 FY2017Sep 30, 2017$15.63M–

More Aquestive Therapeutics figures

See a number that looks wrong?